KRAS and non-small cell lung carcinoma: The Agilent Resolution ctDx FIRST (Resolution Bioscience, Inc.)is a targeted NGS assay designed to detect a specific mutation in the KRAS gene within cfDNA in plasma samples and thereby help to identify NSCLC patients with certain gene mutations (Pekker et al., 2022).